Deloitte Corporate Finance Advisory acted as the exclusive financial advisor in the sale of Meßmer Medizintechnik to corpuls, a Nordic Capital portfolio company
About the transaction
The Deloitte Corporate Finance Advisory (“CFA”) team under the responsibility of Reiner Schwenk (Managing Director), was led by Christoph Madea (Assistant Director) and supported by Alexander Völkel (Senior Associate) and Laurence Oleownik (Associate). The team provided exclusive sell-side M&A lead advisory services to Ralf Meßmer, the managing shareholder of Meßmer Medizintechnik GmbH (“Meßmer Medizintechnik”), on the successful sale of 100% of the shares to GS Elektromedizinische Geräte G. Stemple GmbH (also known under the brand name “corpuls”), a portfolio company of Swedish private equity firm Nordic Capital.
Meßmer Medizintechnik GmbH, originally founded as Karin Meßmer Medizintechnik GmbH in 1985, is a family-owned business specializing in the distribution and servicing of emergency medical technology. The company offers a range of defibrillators, monitoring systems, and thorax compression devices under exclusive sales and service partnership for corpuls. In addition, Meßmer Medizintechnik actively supports the integration of telemedicine solutions, enabling remote patient monitoring, real-time data transmission, and connected care across pre-hospital and clinical settings. With approximately 30 employees, the company serves a diversified customer base catering to hospitals, emergency medical services, and other medical service providers.
corpuls is a leading global provider medical technology provider, focusing on high-quality, innovative products for professional users in emergency situations. Founded in 1982 by Günter Stemple, it has been majority-owned by Nordic Capital since 2023.
“With this merger, we are laying a common foundation for long-term success and sustainable growth,“ said Dr. Christoph Brönnimann, CEO of corpuls.
The previously authorized signatories of Meßmer Medizintechnik GmbH and newly appointed Managing Directors Stefan Koch and Jörn Schmidt added: “Great opportunities are opening up for us through this merger with one of the leading medical technology manufacturers.”
Deloitte CFA provided tailored M&A lead advisory services and efficiently managed the transaction process, resulting into a value-enhancing outcome for its client. The Deloitte team leveraged its trusted relationship with the corpuls leadership team, which had been further strengthened during the sale of hestomed nord to corpuls in January 2025. The signing and closing of the transaction between corpuls and Meßmer Medizintechnik took place on 30 June 2025.
Legal advice to Meßmer Medizintechnik was provided by LUPP + PARTNER.
About the Client
Based in Landau, Rhineland-Palatinate, Meßmer Medizintechnik is a specialized sales organization of medical devices and related services, targeting the emergency medical market with a focus on Southwestern Germany.
As an authorized, exclusive regional sales partner of corpuls, the company serves customers in Baden-Württemberg, Hesse, Rhineland-Palatinate, and Saarland. Meßmer Medizintechnik has been one of corpuls’ first distribution partners, sharing a successful 40-year partnership.
About the Buyer
The medical technology company based in Kaufering, Bavaria, has been developing and manufacturing innovative high-end devices for emergency and intensive care medicine for over 40 years. With now well over 600 employees, corpuls exports defibrillators, monitoring systems and thorax compression devices for cardiopulmonary resuscitation in the event of cardiac arrest, as well as digital solutions in the field of telemedicine and quality management, to 70 countries worldwide.
About Deloitte – Corporate Finance Advisory
As a leading independent M&A advisor, we provide M&A deal execution and financial advisory services as well as Debt Advisory, to large and mid-market corporations, and private equity firms globally. We offer financial advice and insight at every stage of a transaction – from consideration of strategic options to transaction execution, be it an IPO, acquisition, or divestment, restructuring or carve-out. We pride ourselves on delivering independent, client-focused advice.
Deal contacts:
Reiner Schwenk, Managing Director: +49 152 0931 0467, rschwenk@deloitte.de
Christoph Madea, Assistant Director: +49 151 5800 5122, cmadea@deloitte.de